title: Immunization of noncolonized cystic fibrosis patients against Pseudomonas aeruginosa.
abstract: The long-term safety and immunogenicity of a polyvalent Pseudomonas aeruginosa conjugate vaccine was evaluated in 30 noncolonized cystic fibrosis patients. Four doses were administered over 3 years, and patients were followed for a mean of 38 months. No acute or long-term adverse effects were noted. Immunization engendered a significant antibody response to all vaccine components. A decline in titers during year 3 of observation was associated with a marked rise in the isolation of P. aeruginosa. This organism was isolated repeatedly from the respiratory tract of 4 patients and only once from 7 patients. The remaining patients were repeatedly culture-negative. Only 1 patient showed clinical deterioration associated with multiple isolations of P. aeruginosa.
authors.affiliation: Swiss Serum and Vaccine Institute, Inselspital, University of Berne.
authors.forename: S J
authors.initials: SJ
authors.lastname: Cryz
authors.forename: J
authors.initials: J
authors.lastname: Wedgwood
authors.forename: A B
authors.initials: AB
authors.lastname: Lang
authors.forename: A
authors.initials: A
authors.lastname: Ruedeberg
authors.forename: J U
authors.initials: JU
authors.lastname: Que
authors.forename: E
authors.initials: E
authors.lastname: Fürer
authors.forename: U B
authors.initials: UB
authors.lastname: Schaad
mesh_terms: D000293:Adolescent; D000328:Adult; D001428:Bacterial Vaccines / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000150:complications* / Q000276:immunology; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D011552:Pseudomonas Infections / Q000150:complications / Q000276:immunology / Q000517:prevention & control*
chemical_list: D001428:Bacterial Vaccines